Morepen files first US drug application, eyes generic diabetes market
Morepen’s first US submission targets a late-stage entry into the global diabetes therapeutics market, leveraging a DPP-4 inhibitor with potential competitive timelines and regulatory milestones
We haven't written up this one. Hindu BusinessLine has the full story — the link below goes straight to it.
